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Significance for public health 
The breast cancer risk is evaluated after mammographic exam by the BI-RADS classification of 
lesion. The BI-RADS 3 classified cases comprise a wide class of lesions and their treatment must be 
subjected to multidisciplinary discussion and consideration. Metabolomic analysis of plasma from 
subjects undergoing mammography may give new information on metabolite content and allow a 
better classification for BI-RADS 3 cases.  
 
Abstract 
Background: Patients at risk of breast cancer are submitted to mammography, resulting in a 
classification of the lesions following the Breast Imaging Reporting and Data System (BI-RADS®). 
Due to BI-RADS 3 classification problems and the great uncertainty of the possible evolution of 
this kind of tumours, the integration of mammographic imaging with other techniques and markers 
of pathology, as metabolic information, may be advisable. 
Design and Methods: Our study aims to evaluate the possibility to quantify by gas chromatography-
mass spectrometry (GC-MS) specific metabolites in the plasma of patients with mammograms 
classified from BI-RADS 3 to BI-RADS 5, to find similarities or differences in their metabolome. 
Samples from BI-RADS 3 to 5 patients were compared with samples from a healthy control group. 
This pilot project aimed at establishing the sensitivity of the metabolomic classification of blood 
samples of patients undergoing breast radiological analysis and to support a better classification of 
mammographic cases.  
Results: Metabolomic analysis revealed a panel of metabolites more abundant in healthy controls, 
as 3-aminoisobutyric acid, cholesterol, cysteine, stearic, linoleic and palmitic fatty acids. The 
comparison between samples from BI-RADS 3 and BI-RADS 5 patients, revealed the importance of 
4-hydroxyproline, found in higher amount in BI-RADS 3 subjects. 
Conclusion: Although the low sample number did not allow the attainment of high validated 
statistical models, some interesting data were obtained, revealing the potential of metabolomics for 
an improvement in the classification of different mammographic lesions. 
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Introduction 
Breast cancer is considered a major Public Health concern for its high morbidity and mortality 
rates: EUROSTAT reports that breast cancer accounted for 1.8% of all deaths in the EU-28 in 2015 
and 3.6% of deaths in women.1 The breast cancer risk is evaluated worldwide by the Breast Imaging 
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Reporting and Data System (BI-RADS®) since its introduction in 1992 by the American College of 
Radiology. The BI-RADS System was designed to serve as a guide to provide standardized 
terminology in breast XR imaging.2,3 This recommended reporting structure includes final 
assessment categories with management recommendations and a framework for data collection and 
auditing. The BI-RADS® for mammography was designed to standardize breast image reports and 
to reduce confusion in breast image interpretations. It also facilitates the monitoring of results and 
quality assessment. But, despite the initial wide diffusion of the System, and considering the effort 
to produce free-access tool available on the web for the BI-RADS reporting numerous reports about 
the not univocal tumour classification by this System, as it is used, are reported with challenging to 
reproduce classification, especially for the categories associated with BI-RADS 3 classes.  
Indeed, BI-RADS provides a highly questionable positive predictive reference (PPV) ranges for 3 
(<2%), for 4 (2-95%), and in some cases provides subclassification (4a, b, c) considered as 
unnecessary by several authors. Due to this uncertainty, radiologists continue to have different 
PPVs for identical lesions evaluated by the Radiological Mammography. 
The increasing participation of the population to breast screening programs has led to an increase in 
the diagnosis of the mammographic lesions, particularly for the lesions classified with a degree of 
malignancy (BI-RADS 3) in the BI-RADS classification system. According to the most recent 
literature data, the risk of malignancy of these kinds of lesions varies in the range 9.9-35.1%. The 
benign lesions group includes atypical lobular hyperplasia (LIN 1), classic lobular carcinoma in situ 
(LIN 2) and pleomorphic lobular carcinoma in situ (LIN 3).4 Further, there are the ductal carcinoma 
in situ (DCIS), with different grading, DCIS of low nuclear grade, DCIS of intermediate nuclear 
grade and DCIS of high nuclear grade.4 
To complete the classification of the benign lesion, sclerosing lesions (sclerosing adenosis, radial 
scar), benign phyllodes tumour lesions (the most phyllodes tumors are benign, but in rare cases, 
they can be malignant), breast micro glandular adenosis, mucocele-like lesions and 
adenomyoepithelioma, must be included.5,6 Some of these kinds of lesions are usually classified in 
the BI-RADS 3 group. 
Due to BI-RADS 3 classification problems, the great uncertainty of the possible evolution of these 
kinds of tumours and the need of integration of mammographic imaging with other techniques and 
markers of pathology, as metabolic information, must be recommended. 
This study aims to quantify plasma metabolites in patients with mammograms classified from BI-
RADS 3 to BI-RADS 5 and assessing if there may be a similarity between the metabolome of 
patients with BI-RADS 5 lesions (certainly malignant after VAB Vacuum Assisted Biopsy) and 
patients with BI-RADS 3 lesions (with uncertain potential for malignancy after VAB). Such a broad 
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classification uncertainty should be corrected by a multidisciplinary approach to the pathology 
classification. In the last years many metabolomic studies on breast cancer tried to identify useful 
biomarkers for early diagnosis and pathology degree classification: different bio-samples were 
analysed (plasma, serum, urine, saliva, bioptic tissue) employing different analytical platforms (LC- 
or GC-MS, NMR) but, despite the large number of data and useful suggestions, no definitive and 
univocal molecular biomarker has been identified.7 In this paper, the Metabolomic support to the 
breast cancer diagnosis and classification is presented. This pilot project aimed at establishing the 
sensitivity of the metabolomic classification of blood samples of patients undergoing breast 
radiological analysis, to improve the tumour classification and follow up of these subjects. 
 
Materials and Methods  
Study population  
The study was conducted at the AOU Cagliari University Hospital-Italy, from June 2016 to October 
2017. The written informed consent was obtained from subjects before inclusion in the study. All 
procedures were in accordance with the Helsinki Declaration of 1975, as revised in 2008. Clinical 
data of the study population are reported in Table 1. 
Blood samples were collected from 38 patients submitted to radiological mammography (Amulet 
Innovality, Fujifilm) in the clinical laboratories of the Radio diagnostic Complex Structure of AOU 
Cagliari University Hospital-Italy: 32 subjects were diagnosed with BI-RADS 3 to 5 classification. 
Control samples were collected from 10 healthy subjects. All blood samples were centrifuged at 
2000 rpm for 10 minutes; the surnatant plasma was transferred in Eppendorf safe-lock tubes and 
immediately frozen and stored at -80°C until analysis. 
 
Sample preparation 
Plasma samples were analysed as reported.8 In brief, samples were thawed at 4°C, and 400 μL were 
treated with methanol, mixed with a vortex mixer and then centrifuged. The upper phase was 
transferred in glass vials and evaporated to dryness in an Eppendorf vacuum centrifuge. Fifty μL of 
methoxylamine hydrochloride (0.24 M in pyridine) were added to each sample and left to react for 
17h at room temperature. Then 50 μL of MSTFA (N-Methyl-N-trimethylsilyltrifluoroacetamide) 
were added and left to react for one h at room temperature. Samples were diluted with 100 μL of 
hexane containing the tetracosane (0.015 mg/ml) internal standard and analysed on an Agilent 
5977B Mass Spectrometer interfaced to the GC 7890B equipped with a DB-5ms column (J & W). 
Each acquired chromatogram was analysed using the free software AMDIS (Automated Mass 
Spectral Deconvolution and Identification System; http://chemdata.nist.gov/mass-spc/amdis) 
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supported by an in-house made library, including 300 metabolites. This strategy allowed for the 
detection of 81 compounds: following the identification levels defined by the Metabolomics 
Standards Initiative (MSI)9, 60 were “confidently identified compounds” (level 1), 8 “putatively 
annotated compounds” (level 2), 5 “putatively annotated compound class” (level 3), and eight 
unknown compounds. AMDIS analysis produced an electronic sheet data matrix (Microsoft® 
Excel®, Microsoft Co, Redmond Washington DC, USA) that was submitted to statistical analysis 
as previously described.10 
 
Statistical analysis 
The AMDIS data matrix was processed with the integrated web-based platform MetaboAnalyst 
[http://www.metaboanalyst.ca/].11 Missing values were replaced with half of the minimum positive 
value. After normalization by sum, data were log-transformed and then categorized using the Pareto 
scaling procedure. Statistical procedures include univariate analysis, partial least square 
discriminant analysis (PLS-DA) and orthogonal partial least square discriminant analysis (OPLS-
DA). Variable importance in projection (VIP) score for each model was calculated. PLS-DA 
models were tested with the leave-one-out cross-validation (LOOCV) method for the evaluation of 
statistical parameters (correlation coefficient R2, cross-validation coefficient Q2), which allowed us 
to determine the optimal number of components for the model description. 
 
Results 
The first statistical analysis examined group P, pathologic subjects, compared to group C, healthy 
controls. Univariate analysis (t-test) revealed four metabolites as statistically different between 
groups: 3-aminoisobutyric acid, fructose, 3-hydroxybutyric acid and 2-hydroxybutyric acid. The 
first was found more abundant in controls, while the others were more abundant in the pathological 
group. The PLS-DA model reveals an overlapping between samples but reaches an acceptable level 
of statistical significance, as reported in Figure 1A. The model reveals all metabolites as more 
abundant in pathologic samples except for 3-aminoisobutyric acid, cholesterol, stearic, linoleic and 
palmitic fatty acids, cysteine, and phosphate. 
The low level of Q2 (Q2=0.16) reveals that a simple model with two classes for plasma samples 
from subjects marked by BI-RADS score from 3 to 5, together with the great uncertainty for the 
attribution of BI-RADS score in some cases, justify the low predictive power of the model also 
indicating the need to stratify the samples by the BI-RADS score, providing the comparison of each 
BI-RADS class with the control group. 
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The comparison between BI-RADS 3 subjects (10) and controls (10) resulted in the PLS-DA model 
described in Fig 1B. The comparison between BI-RADS 4 subjects (10) and controls (10) generated 
the PLS-DA model described in Fig 1C. The comparison between BI-RADS 5 subjects (12) and 
controls (10) generated the PLS-DA model described in Fig 1D.  
Table 2 reports the most important metabolites (VIP score >1.0) for the above reported PLS-DA 
models, with the corresponding trend. 
These data revealed some common features between the BI-RADS groups, when compared with the 
control group. 2-Hydroxy- and 3-hydroxybutyric acids, ethanolamine and fructose were found in 
higher amount in all pathological groups, while 3-aminoisobutyric acid and cholesterol were less 
abundant. 
Finally, we compared the BI-RADS 5 with the BI-RADS 3 in order to establish the sensitivity of 
our approach towards differences between different malignity of tumours. The PLS-DA model did 
not reach statistical significance, being characterized by accuracy=0.68182, R2=0.55635, Q2=-
0.040531. The removal of an outlier (sample 16) did not improve the model predictivity, while the 
corresponding OPLS-DA model was characterized by good discriminatory power (Figure 2). 
One metabolite, the 4-hydroxyproline, resulted as the most important in the discrimination between 
classes BI-RADS 3 and BI-RADS 5, being more abundant in the BI-RADS 3 group.  
 
Discussion 
This study reports a novel investigation approach for the breast tumours analysis and classification. 
Usually the BI-RADS system has a significant amount of failures in tumours classification 
especially for the BI-RADS 3 class, a class with borderline characteristics and with difficult 
categorization of a broad typology of tumours. Table 3 reported the most common benign lesions 
classified in BI-RADS 3. 
In case of malignancy suspect after mammography, a biopsy is required. The cells or tissue from 
biopsy are withdrawn by VAB/Core-Biopsy CB or by Excisional Biopsy of the Breast. These 
samples will be histologically classified by means of the Anatomic Pathology techniques to verify 
the presence of tumor.12-13 In all these cases, an upgrade toward malignant lesions diagnosis of 5-
7% of cases is expected. For this reason, the surgical extensions procedures after the VAB recently 
increased (and in some case also by excisional surgery procedures, that is highly discussed in the 
scientific community), even in case of benign lesions, with a general increase of cost for the 
surgical procedures and patient’s stress and overload. Recently, several guidelines have been 
published by the most influential scientific associations about the management of lesions with the 
BI-RADS 3 uncertain malignancy potential, but, to date, there is no univocal positive predictive 
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diagnostic system able to indicate, a priori, which lesions, histologically catalogued as BI-RADS 3, 
should evolve towards higher risk classes also after extended surgery procedures. Since there is no 
characteristic radiological pattern, it is not easy to define whether the biopsy collection has wholly 
removed the lesion or there may be neoplastic or pre-neoplastic alterations accompanying the 
surrounding parenchyma, so it must be based on the positive predictive value (PPV) of these 
injuries. Although the latest edition of the NCCN guidelines always recommends surgical excision, 
many studies do not justify this position.14 In fact, a European Consensus has recently been 
published limiting the use of surgery to adequately selected BI-RADS 3 lesions during the 
multidisciplinary discussion.15 The need to proceed with surgical excision should be based on 
clinical-radiological and histological data, taking into particular consideration the patient's family 
history,16 after adequate informed consent. This is particularly true, especially after VAB sampling, 
in cases where microcalcifications are entirely removed by post-biopsy mammography.12 
In order to improve the sensibility and the specificity, we tested the potential contribution of 
Metabolomics with a pilot study to investigate if GC-MS analysis of plasma samples of patients 
could give a better understanding of the difference between the categories of benign tumors usually 
classified in the BI-RADS 3 class.  
The comparison between pathological samples (BI-RADS 3 to 5) with controls (all together or each 
single BI-RADS group) revealed 2- and 3-hydroxybutyric acid, together with ethanolamine and 
fructose more abundant in pathological samples, while 3-aminoisobutyric acid and cholesterol were 
found in higher amount in healthy subjects. 
2- and 3-hydroxybutyric acid were detected and proposed as diagnostic biomarkers in ovarian 
cancer patients17 and in breast cancer.18 These molecules and their oxidation products are classified 
as ketone bodies: the higher amount found in cancer patients when compared with healthy controls, 
may be ascribed to an upregulated fatty acid oxidation due to the higher energy demand of tumour 
cells. 
3-Aminoisobutyric acid was found in higher amounts in healthy controls: this molecule mainly 
derives from the breakdown of the DNA pyrimidine base thymine (Figure 3): 
Ethanolamine constitutes the polar head of phosphoglycerides, being the second most abundant 
constituent of membranes of this class of lipids. Upregulation in phospholipid metabolism was 
reported in different studies employing a multiplatform approach.18-19 
4-hydroxyproline resulted the most important metabolite in the discrimination between classes BI-
RADS 3 and BI-RADS 5, being more abundant in the BI-RADS 3 group.  
This molecule is an amino acid found almost exclusively in collagen, being responsible of the 
correct folding of its helix polypeptide chains. The proline 4-hydroxylation is a post-translational 
8 
 
process catalysed by Prolyl 4-hydroxylase (P4H). An increase of 4-hydroxyproline amount has been 
connected to collagen degradation.20  
Our study proofs the ability of Metabolomics to distinguish between BI-RADS 3 e BI-RADS 5 
classes, also with limited sample numerosity. Although the statistical models did not reach high 
predictivity values, nevertheless interesting information were obtained about the metabolic profile 
of different BI-RADS classes. 
 
Conclusion 
In this pilot study, we reported the potential contribution of Metabolomics to the radiological 
classification of breast cancer images. Metabolomics represents a powerful tool for the extraction of 
features about the health status of patients with a suspect of breast tumour. As reported in recent 
publications about metabolomics and cancer,7,8,19,21 a fingerprint with the capability to improve 
specificity and sensibility of the radiological classification of tumours can be extracted from the 
peripherical plasma or specific tissue. BI-RADS classification can be enhanced by the 
quantification of the metabolites list from Metabolomics analysis. We found a particular model for 
the differences between BI-3 and BI-5 using peripherical plasma. To establish the correct 
fingerprint and the proper features, the number of samples must be increased, having the reasonable 
assurance that the metabolomic model can work. 
Finally, this study proves that Metabolomic analysis opens an essential gate to the omic data use in 
the Radiological Diagnosis, the Radiometabolomics. 
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Table 1. Clinical characteristics of the study population. Group 1: cases, women submitted to 
mammography; group 2: healthy controls. 
 Group 1 (n=38) 
Group 2 
(n=10) 
Age (mean ± SD) 49±15 48±10 
BI-RADS classification (32) BI-RADS 3 (10) 
BI-RADS 4 (10) 






Table 2. PLS-DA most important metabolites (VIP = variable importance in the projection; VIP 
score > 1) and the relative abundance differences: ↑ more abundant in pathological class (all 
pathological samples (P), BI-RADS 3 (3), BI-RADS 4 (4), BI-RADS 5 (5) compared to controls C); 
↓ less abundant in pathological compared to controls. Chemical class: AA (Amino acid), HA 
(Hydroxy acid), A (Acid), FA (Fatty acid), PO (Polyol), Am (Amine), S (Sugar), St (Steroid), I 
(Inorganic). 
 
Metabolite Chemical class Identification level8 P vs C 3 vs C 4 vs C 5 vs C 
2-Hydroxybutyric acid HA 1 ↑ ↑ ↑ ↑ 
3-Aminoisobutyric acid AA 1 ↓ ↓ ↓ ↓ 
3-Hydroxybutyric acid HA 2 ↑ ↑ ↑ ↑ 
4-Hydroxyproline AA 1  ↑   
Arabitol PO 1 ↑  ↑  
Cholesterol St 1 ↓ ↓ ↓ ↓ 
Citric acid HA 1   ↑  
Cysteine AA 1 ↓ ↓ ↓  
Erythritol PO 1 ↑ ↑ ↑  
Ethanolamine Am 1 ↑ ↑ ↑ ↑ 
Fructose S 1 ↑ ↑ ↑ ↑ 
Glutamic acid AA 1   ↑  
Glyceric acid HA 1 ↑ ↑ ↑  
Iminodiacetic acid A 1    ↓ 
Isoleucine AA 1    ↑ 
Lactic acid HA 1    ↑ 
Leucine AA 1  ↑   
Linoleic acid FA 1 ↓  ↓ ↓ 
Mannose S 1 ↑   ↑ 
Palmitic acid FA 1 ↓  ↓  
Palmitoleic acid FA 1 ↑  ↑ ↑ 
Phenylalanine AA 1 ↑ ↑   
Phosphate I 1 ↓  ↓  
Proline+CO2 AA 1 ↑   ↑ 
Pyroglutamic acid AA 1  ↑   
Pyruvic acid A 1 ↑ ↑ ↑  
Serine AA 1  ↑   
Stearic acid FA 1 ↓  ↓ ↓ 





Table 3. Common benign lesions classified in BI-RADS 3. 
 
Typical pre surgery diagnosis [BI-RADS 3] 
Atypical lobular hyperplasia LIN1 
Classical lobular neoplasia LIN2 
Flat epithelial atypia  
Atypical intraductal proliferation  
Intraductal papilloma 
Elastic sclero/radial scar injury 
Benign phyllodes tumour 
Rare: microglandular adenosis, adenomyoepithelioma, 







Figure 1. PLS-DA score plot between the first two components of the model: A) Pathological 
subjects P (green) vs healthy subjects C (red) (accuracy=0.79167; R2=0.41472; Q2=0.16346. B) BI-
RADS 3 subjects (red) vs healthy subjects C (green) (accuracy=0.7; R2=0.61611; Q2=0.29495). C) 
BI-RADS 4 subjects (red) vs healthy subjects C (green) (accuracy=0.7; R2=0.66387; Q2=0.33798). 





Figure 2. OPLS-DA model obtained from the comparison between BI-RADS 3 and BI-RADS 5. 










Figure 3. Biochemical reaction leading to 3-Aminoisobutyric acid. 
 
